Company
Mirati Therapeutics
Mirati Therapeutics has 17 drugs tracked on RxWires: 3 in Phase 3, 1 in Phase 2/3, 7 in Phase 2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| MRTX849 | Phase 3 | Advanced Colorectal Cancer |
| Nivolumab | Phase 3 | Metastatic Non-Squamous Non-Small Cell Lung Cancer |
| Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Sitravatinib | Phase 2/3 | Advanced or Metastatic Solid Malignancies |
| MGCD0103 | Phase 2 | Lymphoma |
| MGCD0103 and Azacitidine | Phase 2 | Hodgkin Lymphoma |
| Mocetinostat | Phase 2 | Urothelial Carcinoma |
| Abemaciclib | Phase 2 | CDK Gene Mutation |
| MGCD516 | Phase 2 | Liposarcoma |
| Glesatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC |
| MGCD0103 & Docetaxel | Phase 1 | Breast Cancer |
| MGCD265 | Phase 1 | Advanced Malignancies |
| Darlifarnib | Phase 1 | Solid Tumors With HRAS Alterations |
| Pembrolizumab | Phase 1 | Lung Cancer |
| MRTX0902 | Phase 1 | Solid Tumor |
| Durvalumab | Phase 1 | Lung Cancer |
Latest
Follow Mirati Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.